Company intelligence / Profile preview
SPH Biotherapeutics
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SPH Biotherapeutics is developing novel immunotherapies, including a PD1/SNIPR-based ROR1 CAR-T cell therapy that is currently in pre-clinical testing targeting cancer; the company has also developed high affinity antibodies to PD-1 and LAG-3 (bispecific monoclonal antibody) with granted patents but no reported clinical data.
- Therapeutic areas
- Oncology
- Modalities
- CAR-T cell therapyMonoclonal antibodyBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on SPH Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPH Biotherapeutics.